TrialEuropean journal of nuclear medicine and molecular imaging2026

Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.

Irene Marini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.